SEC Form 3 · accession 0001615774-19-000109
Intec Pharma Ltd. · NTEC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nadav Navon
Officer — Chief Operating Officer
Period of report
Jan 1, 2019
Accepted (ET)
Jan 2, 2019 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001638381
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | holding | — | — | — | 19,456 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.14 | holding | — | — | — | — | Mar 27, 2026 | Ordinary Shares | 45,500 | — | D |
| Stock Option (right to buy)F2 | $4.466 | holding | — | — | — | — | Jul 25, 2026 | Ordinary Shares | 50,000 | — | D |
| Stock Option (right to buy)F3 | $5.46 | holding | — | — | — | — | Jul 5, 2024 | Ordinary Shares | 65,000 | — | D |
| Stock Option (right to buy)F4 | $5.19 | holding | — | — | — | — | Jan 2, 2025 | Ordinary Shares | 85,000 | — | D |
Explanation of responses
- F1The stock option vested and became exercisable as to one-quarter of the total shares on March 27, 2017 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through March 27, 2020.
- F2The stock option vested and became exercisable as to one-quarter of the total shares on July 25, 2017 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 25, 2020.
- F3The stock option vested and became exercisable as to one-third of the total shares on July 5, 2018 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 5, 2020.
- F4The stock option vests and becomes exercisable as to one-third of the total shares on January 2, 2019 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through January 1, 2021.
Remarks
The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.